Regeneron Breaks Ground on Its Tarrytown Campus Expansion
A year after announcing it would spend $1.8 billion to expand its research and preclinical manufacturing facilities on its Tarrytown campus, Regeneron Pharmaceuticals broke ground on the project. There to celebrate with co-founders, Drs. Leonard Schleifer and George Yancopoulos, was New York Governor Kathy Hochul along with a host of state and local elected officials basking in the phenomenal success of the $16 billion in sales biotech giant, an early star in the fight against COVID—19.
Regeneron will add at least 1,000 full-time, high-skill jobs as it creates, tests and develops medicines to treat a wide range of diseases. Construction will take place in two phases with completion targeted for 2027. The New York State Empire State Development Corporation is kicking in up to $100 million through Excelsior Jobs Program tax credits.
Dupilumab FDA Approved for AD Patients 6 Months to 5 Years
Sanofi and Tarrytown headquartered Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. This filing is also under review by the European Medicines Agency (EMA) for this age group along with and submissions to regulatory authorities in other countries worldwide. Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin (IL)-4 and IL-13 pathways and is not an immunosuppressant.
Regeneron to Buy Global License Rights to Sanofi’s Libtayo
Sanofi and Regeneron had equally divided the global operating profits of Libtayo and jointly marketed Libtayo in the US with the former overseeing the marketing of the product in the rest of the globe.
A fully human monoclonal antibody, Libtayo acts on the immune checkpoint receptor PD-1 on T cells.
Regeneron will make an upfront payment of $900m to Sanofi as well as a 11% royalty on global net sales of Libtayo.